Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020

View through CrossRef
Introduction: We assessed best available data on access and delivery of acute stroke unit (SU) care, intravenous thrombolysis (IVT) and endovascular treatment (EVT) in the European region in 2019 and 2020. Patients and methods: We compared national data per number of inhabitants and per 100 annual incident first-ever ischaemic strokes (AIIS) in 46 countries. Population estimates and ischaemic stroke incidence were based on United Nations data and the Global Burden of Disease Report 2019, respectively. Results: The estimated mean number of acute SUs in 2019 was 3.68 (95% CI: 2.90–4.45) per one million inhabitants (MIH) with 7/44 countries having less than one SU per one MIH. The estimated mean annual number of IVTs was 21.03 (95% CI: 15.63–26.43) per 100,000 and 17.14% (95% CI: 12.98–21.30) of the AIIS in 2019, with highest country rates at 79.19 and 52.66%, respectively, and 15 countries delivering less than 10 IVT per 100,000. The estimated mean annual number of EVTs in 2019 was 7.87 (95% CI: 5.96–9.77) per 100,000 and 6.91% (95% CI: 5.15–8.67) of AIIS, with 11 countries delivering less than 1.5 EVT per 100,000. Rates of SUs, IVT and EVT were stable in 2020. There was an increase in mean rates of SUs, IVT and EVT compared to similar data from 2016. Conclusion: Although there was an increase in reperfusion treatment rates in many countries between 2016 and 2019, this was halted in 2020. There are persistent major inequalities in acute stroke treatment in the European region. Tailored strategies directed to the most vulnerable regions should be prioritised.
SAGE Publications
Diana Aguiar de Sousa Arlene Wilkie Bo Norrving Chris Macey Claudio Bassetti Cristina Tiu Greg Roth Grethe Lunde Hanne Christensen Jens Fiehler Francesca Romana Pezzella Martin Dichgans Melinda B Roaldsen Peter Kelly Robert Mikulik Simona Sacco Valeria Caso Urs Fischer Entela Basha Nune Yeghiazaryan Stefan Kiechl Rana Shiraliyeva Peter Vanacker Marija Bender Mihael Emilov Tsalta-Mladenov Hrvoje Budincevic Ales Tomek Georgios Kaponides Helle Klingenberg Iversen Jürgen Faiss Janika Kõrv Tiina Sairanen Sibon Igor Alexander Tsiskaridze George Ntaios Georgios Tsivgoulis Laszlo Szapary Bjorn Logi Thorarinsson Joe Harbison Natan M. Bornstein Danilo Toni Jashari Fisnik Kunduz Karbozova Evija Miglane Jatužis Dalius Dirk Droste Maria Mallia Erakovic Jevto Anita Arsovska Annette Fromm Adam Kobayashi Elsa Azevedo Stanislav Groppa Tiu Cristina Alla Guekht Zeljko Zivanovic Vladimir Nosal Bojana Zvan Elena López-Cancio Natàlia Pérez de la Ossa Bo Norrving Krassen Nedeltchev Bert Vrijhoef Mehmet Akif Topcuoglu Yuriy Flomin Rubina Ahmed Andrey Shelesko Mentor Petrela Lina Zubalova Rovshan Hasanov Sylvie De Raedt Mahmutbegović Nevena Silva Peteva Andonova Zdravka Poljakovic Ondrej Skoda Johnsen Søren Paaske Prof. Dr. med. Helmuth Steinmetz Janika Kõrv Tiina Sairanen Sablot Denis Nino Lobjanidze Haralambos Milionis Panagiotis Mitsias Gabor Tarkanyi MD Marianne Elisabeth Klinke David Tanne Petraglia Luca Boshnjaku Dren Dzhamal Turgumbaev Karelis Guntis Jatužis Dalius Dirk Droste Debeljevic Mladen Anita Arsovska Martin Kurz Czlonkowska Anna Zota Eremei Terecoasa Elena Oana Mikhail Martinov Dejana Jovanović Zuzana Gdovinova Bojana Zvan Elena López-Cancio Pol Camps Renom Vincent Kwa Ethem Murat Arsava Maryna Gulyayeva Michelle Dharmasiri Entela Basha Eleni Korompoki Konstantinos Vadikolias Daniel Bereczki MD Anna Bryndis Einarsdottir Blyta Afrim Elmira Mamytova Jurjans Kristaps Rastenytė Daiva Oana Costache Roganovic Milovan Annette Fromm Karlinski Michal Gasnas Alexandru Tuta Sorin Mikhail Fidler Ranko Raičević Marjan Zaletel Mar Castellanos Manuel Gómez-Choco Hadiye Sirin Dmytro Lebedynets Jattinder Khaira Eugen Enesi David Sahakyan Ayten Mammadbayli Robin Lemmens Smajlović Dževdet Mihael Emilov Tsalta-Mladenov Hrvoje Budincevic Martin Sramek med. Darius Nabavi Riina Vibo Daniel Strbian Rahim Aliyev Robert Mikulik David Ozretic Miloslav Rocek Stavngaard Trine Prof. Dr. med. Claus Zimmer Vladislav Malikov Kimmo Lappalainen Berge Jerome Mirza Khinikadze Elias Brountzos Vilhjalmur Vilmarsson Kupcs Karlis Kurminas Marius Michel Hoffmann Reuben Grech Mitric Marija Gaute Kjellevold Wathle Poncyljusz Wojciech Crivorucica Igor Dorobat Bogdan Viktor Till Andrej Klepanec Zoran Milosevic Juan Macho Ozcan Ozdemir Dmytro Shchehlov Damgaard Dorte Peter Hermanek Lela Sturua Olga Siskou Georgios Tsivgoulis Carmit Libruder Bent Indredavik Elsa Azevedo Manole Elena Milija Mijajlović Peter Turcani Bo Norrving Leo Bonati Paul Nederkoorn Muhammed Ertuğrul Eğin Dmytro Samofalov Ose Diana Gaidelytė Rita Dirk Droste
Title: Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020
Description:
Introduction: We assessed best available data on access and delivery of acute stroke unit (SU) care, intravenous thrombolysis (IVT) and endovascular treatment (EVT) in the European region in 2019 and 2020.
Patients and methods: We compared national data per number of inhabitants and per 100 annual incident first-ever ischaemic strokes (AIIS) in 46 countries.
Population estimates and ischaemic stroke incidence were based on United Nations data and the Global Burden of Disease Report 2019, respectively.
Results: The estimated mean number of acute SUs in 2019 was 3.
68 (95% CI: 2.
90–4.
45) per one million inhabitants (MIH) with 7/44 countries having less than one SU per one MIH.
The estimated mean annual number of IVTs was 21.
03 (95% CI: 15.
63–26.
43) per 100,000 and 17.
14% (95% CI: 12.
98–21.
30) of the AIIS in 2019, with highest country rates at 79.
19 and 52.
66%, respectively, and 15 countries delivering less than 10 IVT per 100,000.
The estimated mean annual number of EVTs in 2019 was 7.
87 (95% CI: 5.
96–9.
77) per 100,000 and 6.
91% (95% CI: 5.
15–8.
67) of AIIS, with 11 countries delivering less than 1.
5 EVT per 100,000.
Rates of SUs, IVT and EVT were stable in 2020.
There was an increase in mean rates of SUs, IVT and EVT compared to similar data from 2016.
Conclusion: Although there was an increase in reperfusion treatment rates in many countries between 2016 and 2019, this was halted in 2020.
There are persistent major inequalities in acute stroke treatment in the European region.
Tailored strategies directed to the most vulnerable regions should be prioritised.

Related Results

Iranian stroke model-how to involve health policymakers
Iranian stroke model-how to involve health policymakers
Stroke in Iran, with more than 83 million population, is a leading cause of disability and mortality in adults. Stroke has higher incidence in Iran comparing the global situation a...
HIPERTENSI, USIA, JENIS KELAMIN DAN KEJADIAN STROKE DI RUANG RAWAT INAP STROKE RSUD dr. M. YUNUS BENGKULU
HIPERTENSI, USIA, JENIS KELAMIN DAN KEJADIAN STROKE DI RUANG RAWAT INAP STROKE RSUD dr. M. YUNUS BENGKULU
Hypertension, Age, Sex, and  Stroke  Incidence In Stroke Installation Room RSUD dr. M. Yunus BengkuluABSTRAKStroke adalah gejala-gejala defisit fungsi susunan saraf yang diakibatka...
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
According to epidemiological studies, the leading cause of morbidity, disability and mortality are cerebrovascular diseases, in particular ischemic and hemorrhagic strokes. In rece...
Dyselectrolytaemia in Acute Stroke Patients, an Observational Study
Dyselectrolytaemia in Acute Stroke Patients, an Observational Study
Background: There are many studies on stroke, its associated conditions and their effect on stroke patient’s outcome, but a few studies on dyselectrolytaemia in stroke patients has...
Clinical Features, Risk Factors and Hospital Mortality of Acute Stroke Patients
Clinical Features, Risk Factors and Hospital Mortality of Acute Stroke Patients
Background: Stroke is a leading cause of mortality and disability worldwide. To prevent complications and permanent defects, early diagnosis, distinguishing the type and risk facto...
Heterogeneity among women with stroke: health, demographic and healthcare utilization differentials
Heterogeneity among women with stroke: health, demographic and healthcare utilization differentials
Abstract Background Although age specific stroke rates are higher in men, women have a higher lifetime risk and are more likely to die from a stroke...
Degeneration of structural brain networks is associated with cognitive decline after ischaemic stroke
Degeneration of structural brain networks is associated with cognitive decline after ischaemic stroke
Abstract Over one third of stroke patients have long-term cognitive impairment. The likelihood of cognitive dysfunction is poorly predicted by the location or size o...
Promising Strategies for the Development of Advanced In Vitro Models with High Predictive Power in Ischaemic Stroke Research
Promising Strategies for the Development of Advanced In Vitro Models with High Predictive Power in Ischaemic Stroke Research
Although stroke is one of the world’s leading causes of death and disability, and more than a thousand candidate neuroprotective drugs have been proposed based on extensive in vitr...

Back to Top